Clinton Health Access Initiative

Today at , six countries — Ethiopia, Ghana, Honduras, Nigeria, Senegal, and Zambia — pledged over US$185 million to expand access to contraceptives and life-saving maternal and newborn health supplies.

It's one of the largest recent government financing commitments for reproductive and maternal health and it's not a coincidence that the number matches the US$185 million gap in contraceptive funding that aid cuts are projected to leave in 2026 alone.

Alongside these commitments, CHAI, Unitaid, and UNFPA are launching a new market-shaping partnership to expand access to the calibrated drape, a low-cost device that helps health workers detect postpartum hemorrhage early and trigger timely treatment. Postpartum hemorrhage is a leading cause of maternal death worldwide.

https://ow.ly/Ovw250Z3bX0

, a twice-yearly injectable HIV prevention drug, is now reaching people in low- and middle-income countries. A new flash market update tracks where rollout stands and what comes next.

• Eight African countries have introduced lenacapavir for PrEP
• More than 11,000 people initiated so far
• Across all ten early adopter countries, more than 600,000 people are projected to start lenacapavir this year
• Fourteen more countries are planning launches by end of 2026 or early 2027

The report also tracks progress toward generic market entry — which will be critical to bring costs down and reach the people who need it most. https://ow.ly/BE1550Z2onB

Wits RHI, Unitaid

As WHA discussions continue in Geneva, one question deserves more attention: not just who makes vaccines, but whether regional manufacturers can stay in business long enough to deliver those vaccines.

Both Latin America and Southeast Asia have established vaccine manufacturers and made meaningful progress. Yet several challenges are weakening the regional manufacturing base. Technology transfer agreements often cap where products can be sold, demand signals across countries remain fragmented, and regulatory systems create friction for supply moving across borders. The hard part of regional vaccine manufacturing isn't building the capacity. It's making sure manufacturing is "fit-for-purpose."

Our two new whitepapers lay out what that requires:

Latin America: https://ow.ly/jlt750Z0m87

Southeast Asia: https://ow.ly/z7HW50Z0m85

Latin America went from sourcing less than 1% of its vaccines regionally to 23% in five years. That's a real shift.

But building capacity and sustaining it are two different challenges.

New research from CHAI and RVMC finds that most regional manufacturers are still confined to their home markets, and government purchasing commitments remain limited, making it difficult for manufacturers to plan and invest with confidence.

As global health leaders gather in Geneva this week, we're publishing new findings on what it actually takes to make regional vaccine manufacturing sustainable — and what needs to change to get there.

https://ow.ly/HxwP50Z0lIW